摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3R,4R)-1-methylpyrrolidine-3,4-diyl di((9Z,12Z)-octadec-9,12-dienoate) | 1346225-67-9

中文名称
——
中文别名
——
英文名称
(3R,4R)-1-methylpyrrolidine-3,4-diyl di((9Z,12Z)-octadec-9,12-dienoate)
英文别名
[(3R,4R)-1-methyl-4-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypyrrolidin-3-yl] (9Z,12Z)-octadeca-9,12-dienoate
(3R,4R)-1-methylpyrrolidine-3,4-diyl di((9Z,12Z)-octadec-9,12-dienoate)化学式
CAS
1346225-67-9
化学式
C41H71NO4
mdl
——
分子量
642.019
InChiKey
WKJBQJHMGQXRLH-FJJAYQCJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    13.5
  • 重原子数:
    46
  • 可旋转键数:
    32
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.76
  • 拓扑面积:
    55.8
  • 氢给体数:
    0
  • 氢受体数:
    5

文献信息

  • LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
    申请人:Manoharan Muthiah
    公开号:US20120058144A1
    公开(公告)日:2012-03-08
    The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures XIV or XVII.
    本发明提供了有利于在体内向细胞传递治疗剂的脂质体中使用的脂质。特别地,本发明提供了具有以下结构XIV或XVII的脂质。
  • PRODUCTION OF A COMPOSITION CONTAINING A COMPLEX BETWEEN A MEMBRANE COMPOSED OF A LIPID MONOLAYER AND A NUCLEIC ACID, AND, A LIPID MEMBRANE FOR ENCAPSULATING THE COMPLEX THEREIN
    申请人:Kyowa Hakko Kirin Co., Ltd.
    公开号:EP3301086A1
    公开(公告)日:2018-04-04
    The present invention relates to a method for producing a composition containing a complex between a membrane composed of a lipid monolayer (reversed micelle) and a nucleic acid, and a lipid membrane for encapsulating the complex therein, comprising the following steps A to D: Step A: preparing a complex between the nucleic acid and a liposome comprising a cationic lipid represented by the formula (I) and/or a cationic lipid other than cationic lipid represented by the formula (I); Step B: preparing a dispersion liquid by dispersing the complex in water or ethanol aqueous solution; Step C: preparing a solution by dissolving the formula (I) and/or the cationic lipid other than cationic lipid represented by the formula (I) in ethanol or an ethanol aqueous solution; and Step D: mixing the dispersion liquid and the solution, and optionally adding water; wherein the formula (I) is (wherein: R1 and R2 are, the same or different, each linear or branched alkyl, alkenyl or alkynyl having 12 to 24 carbon atoms, X1 and X2 are hydrogen atoms, or are combined together to form a single bond or alkylene, X3 is absent or is alkyl having 1 to 6 carbon atoms, or alkenyl having 3 to 6 carbon atoms, when X3 is absent, Y is absent, a and b are 0, L3 is a single bond, R3 is alkyl having 1 to 6 carbon atoms, alkenyl having 3 to 6 carbon atoms, or alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms substituted with 1 to 3 substituent(s), which is(are), the same or different, amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, or dialkylcarbamoyl, and L1 and L2 are -O-, Y is absent, a and b are, the same or different, 0 to 3, and are not 0 at the same time, L3 is a single bond, R3 is alkyl having 1 to 6 carbon atoms, alkenyl having 3 to 6 carbon atoms, or alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms substituted with 1 to 3 substituent(s), which is(are), the same or different, amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, or dialkylcarbamoyl, L1 and L2 are, the same or different, -O-, -CO-O- or -O-CO-, Y is absent, a and b are, the same or different, 0 to 3, L3 is a single bond, R3 is a hydrogen atom, and L1 and L2 are, the same or different, -O-, -CO-O- or -O-CO-, or Y is absent, a and b are, the same or different, 0 to 3, L3 is -CO- or -CO-O-, R3 is alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms substituted with 1 to 3 substituent(s), which is(are), the same or different, amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, or dialkylcarbamoyl, wherein at least one of the substituents is amino, monoalkylamino, dialkylamino, or trialkylammonio, and L1 and L2 are , the same or different, -O-, -CO-O- or -O-CO-, and when X3 is alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms, Y is a pharmaceutically acceptable anion, a and b are, the same or different, 0 to 3, L3 is a single bond, R3 is alkyl having 1 to 6 carbon atoms, alkenyl having 3 to 6 carbon atoms, L1 and L2 are, the same or different, -O-, -CO-O- or -O-CO-).
    本发明涉及一种生产含有由脂质单层(反向胶束)组成的膜与核酸之间的复合物的组合物以及用于将复合物包封在其中的脂质膜的方法,包括以下步骤A至D: 步骤 A:制备核酸与由式(I)代表的阳离子脂质和/或除式(I)代表的阳离子脂质以外的阳离子脂质组成的脂质体之间的复合物; 步骤 B:将复合物分散于乙醇溶液中,制备分散液; 步骤 C:将式(I)和/或式(I)代表的阳离子脂质以外的阳离子脂质溶解在乙醇乙醇溶液中,制备溶液;以及 步骤 D:混合分散液和溶液,可选择加; 其中式 (I) 为 (其中 R1 和 R2 相同或不同,各自为具有 12 至 24 个碳原子的直链或支链烷基、烯基或炔基、 X1 和 X2 为氢原子,或结合在一起形成单键或亚烷基、 X3 不存在或为具有 1 至 6 个碳原子的烷基或具有 3 至 6 个碳原子的烯基、 当 X3 不存在时 Y 不存在,a 和 b 为 0,L3 为单键,R3 为具有 1 至 6 个碳原子的烷基、具有 3 至 6 个碳原子的烯基、或具有 1 至 6 个碳原子的烷基或具有 3 至 6 个碳原子的烯基,这些取代基相同或不同,为基、单烷基基、二烷基基、三烷基基、羟基、烷氧基、基甲酰基、单烷基基甲酰基或二烷基基甲酰基,且 L1 和 L2 为 -O-、 Y 不存在,a 和 b 相同或不同,为 0 至 3,且同时不为 0,L3 为单键,R3 为具有 1 至 6 个碳原子的烷基、具有 3 至 6 个碳原子的烯基,或具有 1 至 6 个碳原子的烷基或具有 3 至 6 个碳原子的烯基被 1 至 3 个取代基取代、L1和L2是相同或不同的基、单烷基基、二烷基基、三烷基基、羟基、烷氧基、基甲酰基、单烷基基甲酰基或二烷基基甲酰基,-O-、-CO-O-或-O-CO-、 Y 不存在,a 和 b 是相同或不同的 0 至 3,L3 是单键,R3 是氢原子,L1 和 L2 是相同或不同的 -O-、-CO-O- 或 -O-CO-,或 羟基、烷氧基、基甲酰基、单烷基基甲酰基或二烷基基甲酰基,其中至少一个取代基是基、单烷基基、二烷基基或三烷基基,且 L1 和 L2 是相同或不同的 -O-、-CO-O- 或 -O-CO-,以及 当 X3 是具有 1 至 6 个碳原子的烷基或具有 3 至 6 个碳原子的烯基时,Y 是药学上可接受的阴离子,a 和 b 是相同或不同的 0 至 3,L3 是单键,R3 是具有 1 至 6 个碳原子的烷基或具有 3 至 6 个碳原子的烯基,L1 和 L2 是相同或不同的-O-、-CO-O-或-O-CO-)。
  • CATIONIC LIPID
    申请人:Kyowa Hakko Kirin Co., Ltd.
    公开号:EP2567951B1
    公开(公告)日:2018-09-19
  • METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS
    申请人:Hope Michael J
    公开号:US20130017223A1
    公开(公告)日:2013-01-17
    A lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties.
  • US8722082B2
    申请人:——
    公开号:US8722082B2
    公开(公告)日:2014-05-13
查看更多